Floatz Rating
B60/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05198830CT.gov Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT02535325CT.gov Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Large Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Methoxyamine (this asset) | National Cancer Institute (NCI) | P2 | B · 60 |
| Carboplatin | National Cancer Institute (NCI) | P4 | A |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BBB |
| Etoposide | Barbara Ann Karmanos Cancer Institute | P3 | BBB |
| Gefitinib | National Cancer Institute (NCI) | P3 | BB |
| Vinorelbine Ditartrate | AIO-Studien-gGmbH | P3 | BB |
| Docetaxel | Korean South West Oncology Group | P3 | BB |
| Cetuximab | SWOG Cancer Research Network | P3 | BB |
| Shark Cartilage Extract | National Cancer Institute (NCI) | P3 | BB |
+23 more in the Lung Large Cell Carcinoma cohort
Other indications for Methoxyamine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P1/2 | B · 59 |
| Lung Adenocarcinoma | — | P2 | B · 58 |
| Adult Glioblastoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Methoxyamine in Lung Large Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/methoxyamine-lung-large-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →